Skip to content

alglucosidase alfa

BIOLOGICAL16 trials

Sponsors

Genzyme, a Sanofi Company, Amicus Therapeutics, Taipei Veterans General Hospital, Taiwan

Conditions

Acid Maltase DeficiencyAcid Maltase Deficiency (AMD)Acid Maltase Deficiency DiseaseGlycogen Storage DiseaseGlycogen Storage Disease Type IIGlycogen Storage Disease Type II (GSD II)Glycogen Storage Disease Type II (GSD-II)Glycogenesis 2 Acid Maltase Deficiency

Phase 2

Phase 3

Phase 4

Late-Onset Treatment Study Extension Protocol
CompletedNCT00455195
Genzyme, a Sanofi CompanyAcid Maltase Deficiency (AMD), Glycogenesis Type II, Glycogen Storage Disease Type II (GSD-II) +1
Start: 2007-03-31End: 2008-11-30Updated: 2014-03-07
High Dose or High Dose Frequency Study of Alglucosidase Alfa
CompletedNCT00483379
Genzyme, a Sanofi CompanyGlycogenesis 2 Acid Maltase Deficiency, Glycogen Storage Disease Type II (GSD-II), Pompe Disease
Start: 2007-05-31End: 2010-07-31Updated: 2014-03-07
Growth and Development Study of Alglucosidase Alfa
CompletedNCT00486889
Genzyme, a Sanofi CompanyAcid Maltase Deficiency Disease, Glycogen Storage Disease Type II (GSD-II), Pompe Disease
Start: 2008-08-26End: 2021-11-23Updated: 2022-08-26
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
CompletedNCT00701129
Genzyme, a Sanofi CompanyGlycogen Storage Disease Type II, Pompe Disease
Start: 2009-10-31End: 2013-03-31Updated: 2014-05-13
Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
CompletedNCT01288027
Genzyme, a Sanofi CompanyGlycogenesis 2 Acid Maltase Deficiency, Glycogen Storage Disease Type II (GSD II), Pompe Disease (Late-Onset)
Start: 2011-06-30End: 2013-12-31Updated: 2014-12-19
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
CompletedNCT01410890
Genzyme, a Sanofi CompanyGlycogen Storage Disease Type II (GSD II), Pompe Disease
Start: 2014-11-03End: 2020-11-20Updated: 2022-03-28
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
TerminatedNCT01526785
Genzyme, a Sanofi CompanyPompe Disease
Start: 2012-03-31End: 2014-12-31Updated: 2015-12-08
A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease
TerminatedNCT01597596
Genzyme, a Sanofi CompanyAcid Maltase Deficiency, Glycogenosis 2, Glycogen Storage Disease Type II (GSD II) +1
Start: 2012-08-31End: 2014-12-31Updated: 2016-01-18
Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen
CompletedNCT04676373
Genzyme, a Sanofi CompanyPompe's Disease
Start: 2021-03-10End: 2024-07-25Updated: 2025-02-10

Unknown Phase

Related Papers

Journal of Neuromuscular Diseases2022-09-015 citations

2 more papers not shown